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A better understanding of multimolecular interactions involved in tumor dissemination is required to identify new effective
therapies for advanced prostate cancer (PCa). Several groups investigated protein-glycan interactions as critical factors for crosstalk
between prostate tumors and their microenvironment.This review both discusses whether the “galectin-signature” might serve as a
reliable biomarker for the identification of patients with high risk of metastasis and assesses the galectin-glycan lattices as potential
novel targets for anticancer therapies.The ultimate goal of this review is to convey how basic findings related to galectins could be
in turn translated into clinical settings for patients with advanced PCa.
1. Introduction
Prostate cancer (PCa) is the second most common cancer in
men and represents a significant cause ofmortalityworldwide
[1]. About 15%–20% of men with PCa will certainly develop
metastatic disease and die. Early diagnosis and rapid treat-
ment play a critical role in the final outcome of the disease.
At present, surgical and radiation treatments are efficient
against clinically localized PCa, whereas androgen ablation
is mainly recommended for advanced PCa [2]. However,
metastatic cancer is essentially fatal due to disease evolution
towards a castration-resistant PCa (CRPC). Novel alternative
approaches are therefore essential to prevent tumor dissemi-
nation and progression to this incurable stage.
Effective cancer therapies for PCa typically capitalize
on molecular differences between healthy and neoplastic
tissues that can be targeted with drugs [3]. In the past years,
delineating gene and protein expression profiles has been
critical in dissecting the molecular underpinnings of cellular
function; the arising information has been exploited for the
design of rational therapeutic strategies. In the postgenomic
era, the study of the “glycome” has enabled the association of
specific glycan structures with the transition from normal to
neoplastic tissue [4]. Glycans abundantly decorate the surface
of all mammalian cells and the extracellular matrix with
which they interact [5]. In general, mammalian glycans are
the product of a repertoire of glycosyltransferases and gly-
cosidases acting sequentially and dictating the glycosylation
signature of each cell type [6]. It has been recognized that the
structure of cell surface glycans can change under different
physiological and pathological conditions. In fact, malignant
transformation is associated with abnormal glycosylation
resulting in the synthesis of altered glycan determinants in the
tumor microenvironment [7].The responsibility of decoding
the information displayed by cell surface glycan structures
is attributed in part to endogenous glycan-binding proteins
or lectins, whose expression and function are also regulated
during oncogenesis and metastasis [8].
Galectins (Gals) are a family of evolutionarily conserved
glycan-binding proteins characterized by their affinity for
N-acetyllactosamine sequences which can be displayed on
cell surface glycoconjugates [9, 10]. Through this type of
interactions, Gals promote lattice formation, strengthening
the avidity and half-life of ligand/receptor interactions, and
organize centers for molecular signaling [11].Therefore, these
particular lectins are the molecular links between changes in
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glycophenotype and signaling processes that underlie cellular
responses to exogenous stimuli. In addition, Gals are also
involved in endogenous regulation of different intracellular
pathways with high impact on controlling cellular behavior
[12–14].
Interestingly, alterations in Gal expression are observed
in pathologic processes such as inflammation, cancer, and
autoimmunity [9, 15–17]. A series of studies in experimental
models and cancer patients have reported significant asso-
ciations among the expression of Gals and tumorigenesis,
metastatic potential, and tumor-immune escape.This review
focuses on the role of Gals in PCa progression and how
could they be used as diagnostic markers of PCa evolution as
well as new therapeutic targets for metastatic and castration-
resistant PCa (mCRPC) patients.
2. Basic Biochemistry and Molecular
Biology of Galectins
Galectins are a family of fifteen described lectins that bind
to the carbohydrate portion of cell surface glycoproteins
or glycolipids and are defined by at least one carbohydrate
recognition domain (CRD) with affinity for beta-galactosides
through a conserved sequence motif [18]. However, each
of the members of this family has subtle differences in
their glycan-binding specificity and tissue distribution (for
detailed information see The Center of Functional Gly-
comics (CFG) database http://www.functionalglycomics.org/
CFGparadigms/index.php/Main Page). Members of the Gal
family are found in vertebrates, invertebrates, and protists;
Gal-related sequences have also been found in plants and
viruses. The high degree of conservation of Gal sequences
suggests that they have an important role in basic cellular
mechanisms [19, 20]. However, from the fifteen defined
members only 11 are expressed in humans (see Table 1, [18]).
Galectins have been subdivided into three groups
(Figure 1(a)) based on their structure and the number of
CRD: (a) prototype Gals are constituted by a single CRD
(Gals-1, -2, -5, -7, -10, -11, -13, and -14); (b) tandem-repeat
Gals, by 2 different but homologous CRDs, connected by a
linker region (Gals-4, -6, -8, -9, and -12); (c) chimera-Gals,
represented by a unique member: Gal-3, consisted by a single
CRD fused to a tail of short tandem repeats. These different
structures allow oligomerization of Gals required for effective
signaling through binding to cell surface glycoconjugates
containingN-acetyllactosaminemoieties (Figures 1(b) and 2)
[11]. As an example, Gal-3 is a chimera-type Gal containing
a single carbohydrate recognition domain (CRD) with an
extended proline and glycine rich-N-terminus that promotes
oligomerization towards highly structured forms. As other
Gals, extracellular andmembrane triggered functions of Gal-
3 strongly depend on CDR-mediated recognition of glycan
chains on glycoproteins, inducing the assembly of lattices in
membrane through direct engagement of specific cell surface
glycoconjugates by traditional ligand-receptor binding [10].
Galectins are synthesized in the cytoplasm and secreted
using a nonclassical pathway [44]; thus, these lectines are
found in a variety of intracellular compartments, as well
as in the extracellular milieu of almost all cell types and
tissues. Membrane-bound or soluble forms of Gals have been
described with some different functions: it is well established
that glycoconjugate recognition byGals plays key roles during
anoikis resistance, metastatic dissemination, and escape of
tumor cells from the immune response (see for review [9,
45]).
Galectins could be affected by posttranscriptional modi-
fications such as cleavage or phosphorylation. In fact, phos-
phorylation or proteolysis affects Gal-3 structure and local-
ization altering important biologic functions of this lectin in
human carcinomas [46–48]. Gal-3 cleavage by matrix met-
alloprotease (MMP)-2/-9 is observed in breast and prostate
cancers and is responsible for tumor growth, angiogenesis,
and apoptosis resistance in mouse models and influence cell
migration, angiogenesis, and tumor progression [48, 49].
The expression pattern of different Gals changes during
tissue development and is altered at sites of inflammation and
tumor. Different reports in colon, breast, prostate, thyroid,
and laryngeal cancers have demonstrated an important role
of Gals in tumor emergence and progression (see for review
[15]). At this respect, the expression level of some Gals by
tumor cells has been shown to be correlated with metastatic
potential. Gals can contribute to tumor progression through
many different mechanisms [50, 51]. Most studies have
evaluated defined Gals, particularly Gals-1 and -3. However,
existing data indicate that other Gals, especially those whose
expression is altered in cancer, probably contribute to various
steps in tumor progression. Mechanisms by which those
Gals are involved in such effects remain poorly understood
especially in the PCa field.
3. Expression of Galectins in Normal and
Cancerous Human Prostate Tissues
Few studies investigated the expression of Gals in normal
prostate [52, 53] and Gals-1; -3, and -8 are the most studied
proteins in prostate carcinoma [23, 29, 52–55]. Pioneer stud-
ies by Lotan’s group found that Gal-1 and Gal-3 are expressed
in the cytoplasm of the majority of prostate cancer cell lines,
except LNCaP which is the most studied human androgen-
sensitive cell line. In fact, LNCaP does not express both Gals
[25]. It is important to note that although LNCaP cells were
clearly negative for Gal-1 expression in this first published
work, we and others have demonstrated that LNCaP cell line
does express low levels of Gal-1mRNA and these transcripts
are upregulated when cells underwent castration resistance
(CR) [56]. In our study, we were able to detect the expression
of Gal-1 at transcriptional levels with a 20-fold lower level
when compared with androgen unresponsive 22Rv1 and PC-
3 cells (Figure 3(a)). Additionally, we have been able to detect
low protein levels by immunocytochemistry and western blot
(see Figure 3(a)). Evenmore, LNCaP cells that have been ren-
dered androgen unresponsive (by culturing them for several
weeks in the absence of hormones) expressed higher levels
of Gal-1 as detected by RT-qPCR (see Figure 3(b), left panel).
Our studies have been performed on cells in the log phase
of growth, as we used to observe variation of Gal expression
Prostate Cancer 3
Table 1: Summary of reported galectin functions in prostate cancers.
Galectin Tumor cell growth/survival/apoptosis Metastasis Immune response
In vitro In vivo In vitro In vivo In vitro In vivo
Gal-1
Promotes apoptosis in
LNCaP [21]
O-glycosylation protects
PCa cell from
Gal-1-induced apoptosis
[22]
Promotes tubulogenesis
[23]
Gal-1 principal inducer
of neovascularization
[23]
Promotes cell adhesion
to ECM, EC [24, 25]
Osteoblasts proliferation
and differentiation,
effects inhibited by IGF
[26]
?
Invasion of T
cell in
matrigel
assays and
adhesion of T
cell to Gal-1-
expressing
EC [27]
?
Gal-3
Promotes apoptosis or
survival depending of
cell subcellular
localization or cell type
[28–30]
Drug resistance
[31, 32]
Gal-3 as inducer of
angiogenesis [33]
Interaction with blood
vessel allowing
metastasis process such
as arrest in certain
organs
[34, 35]
PCa cell with
preferential binding to
HBME through collagen
XXIII and Gal-3 could
explain bone metastasis
[36, 37]
Anti-Gal-3 Abs or
MCP inhibits
spontaneous metastasis
in Copenhagen
rat-injected Dunning
rat PCa cells [38],
influences bone
metastasis as indirect
inhibition of Gal-3, and
inhibits skeleton
metastasis after
Luc-PC-3 intracardiac
injection [39]
Using Gal-3 inhibitors
inhibits tumor growth
or lung metastasis
[33, 40, 41]
? ?
Gal-8
Exclusive expression at
the neoplasic stage in
prostate tissue (PCTA-1);
links to integrin to
inhibit cell adhesion [42]
?
Links to integrin to
inhibit cell adhesion and
promote metastasis and
cell spreading. In
contrary, in soluble form
Gal-8 promotes
cell-adhesion to ECM
[43]
? ? ?
Gal-4 Gal-4 as inducer oftubulogenesis [33] ? ? ? ? ?
Gal-9 Gal-9 as inducer oftubulogenesis [33] ? ? ? ? ?
Gal-12 ? ? ? ? ? ?
Others
Gals ? ? ? ? ? ?
depending on cell culture conditions such as confluency (data
not shown), situation that is not referred to in previous cited
references. Moreover, two different sources of androgen-
responsive and PSA/Gal-1-producing LNCaP cells were eval-
uated as we do infer that some phenotypic differences may
appear in such largely used PCa cell line (Figure 3(b), right
panel). Results clearly demonstrate that the LNCaP cell
line (either castration-sensitive or a clone that undergoes
castration-resistant) as well as a PSA-negative LNCaP clone
(selected in vitro by Vaarala and colleagues [56]) is able
to produce Gal-1, at least under some culture conditions.
However, when expressed, Gal-1 plays an important function
in cell-extracellular matrix (ECM) interactions, conferring
adhesion properties to some PCa cell lines. Gals-1 and -3 have
been thus suggested to play a role in the development and
progression of cancer [25].
Studying the role of Gals in PCa cell lines is certainly not
enough to validate relevance in the human pathology. For
clinical relevance, Lotan’s group has studied by immunohis-
tochemistry (IHC) the expression of Gals in normal human
prostate tissue and prostate adenocarcinoma, containing
formalin-fixed, paraffin-embedded sections of 7 normal
human prostates, 8 cases of prostatic intraepithelial neoplasia
(PIN), 20 primary adenocarcinomas of the prostate, and 12
PCa metastases. Gal-1 was expressed in most cases, irrespec-
tive of the histology stages. In contrast, Gal-3 expression
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Chimera-type
galectin-3
Tandem repeat type
Prototype
galectins-1, -2, -5, -7, -10,
-11, -13, -14, and -15
galectins-4, -6, -8, -9, and -12
(a) Galectins types
Lattice formation
Cell-ECM interactions
Intracellular signal transduction
ECM
Glycoproteins 
Plasmic membrane
(b) Extracellular galectins-glycans interactions
Figure 1: Interactions of galectins with extracellular glycoconjugates.
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Figure 2: Glycans biogenesis and galectins recognition. (a) N-Glycans and (b) O-Glycans.
significantly decreased in primary carcinoma and metastatic
disease compared with normal and premalignant tissue,
suggesting that loss of Gal-3 expression may be associated
with the evolution of the disease [52]. Additionally, analyses
of theGal-1 expression in 148 human primary PCa samples by
IHC revealed that this Gal was not detected in normal, PIN,
or carcinoma cells but accumulated in the stroma, including
associated fibroblasts. Gal-1was significantly increased in the
tumor-associated stroma compared with the nonneoplastic
gland-associated stroma in more than 21% of the cases. The
authors hypothesized that the accumulation of Gal-1 in the
stroma of malignant tissue may indicate both a possible role
for this Gal in the acquisition of an invasive phenotype and
poor prognosis [53].
Furthermore, alteration in the nuclear/cytoplasmic
expression ratio of Gal-3 correlates with PCa progression
[54], and decreasing expression of Gal-3 in benign, adjacent-
benign, and tumor tissues suggests that Gal-3 expression
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Figure 3: Galectin-1 expression in LNCaP cells. (a) Protein levels of Gal-1 in castration sensitive LNCaP and castration resistant 22Rv1 and
PC-3 PCa cell lines. (b) Transcriptional levels of Gal-1 in castration sensitive (CS) or resistant (CR) LNCaP cells. Induction of prostate specific
antigen (PSA) in response to androgen receptor agonist (R18.81; 3 days, 10−10 M) is shown in both cases as fold change between cultures in
absence of hormones and in presence of R18.81. Cells were cultured in absence of hormones (medium complemented with 10% stripped
charcoal-treated serum) for 48 h and then cultured for 3 days in absence or presence of R18.81 (10−10 M) before mRNA extraction and RT-
qPCR for Gal-1 and PSA expression analyses.
could be useful for predicting biochemical recurrence [55].
Moreover, Raz’s group was the first to show Gal-3 as a cell
adhesionmolecule involved in tumor progression [29]. In this
study, IHC analysis revealed that Gal-3 is cleaved during the
progression of PCa, implicating this Gal both as a diagnostic
marker and therapeutic target for future disease treatments
[29]. Not only Gal-3 expression levels but also its cleavage by
matrixmetalloprotease (MMP)-2/-9 are related to both breast
and prostate cancers and are responsible for tumor growth,
angiogenesis, and apoptosis resistance in mouse models
[48]. Increased chemotaxis, invasion, and interactions with
endothelial cells resulting in angiogenesis and morphologic
changes are induced by transfecting BT-459, a Gal-3 negative
breast cancer cell line, with either cleavable full-length Gal-3
or its fragmented peptides [48]. Additionally, amino acids
1–62 and 33–250 from cleaved Gal-3 were identified to
stimulate migration and morphogenesis of endothelial cells.
Thus, cleavage of the aminoterminus of Gal-3 followed by
its release in the tumor microenvironment leads in part to
breast cancer angiogenesis and progression [48]. In PCa,
Gal-3 functions are dependent on both its localization [30]
and posttranslational modifications such as cleavage and
phosphorylation. Gal-3 can be phosphorylated at Tyr-107
by c-Abl and then cleaved between Tyr107 and Gly108 by
prostate-specific antigen (PSA) [49]. Similarities in the role
of cleaved Gal-3 with breast cancer could be postulated:
Gal-3 cleavage results in loss of lectin multivalency while
preserving its carbohydrate binding activity.The authors also
showed that Tyr-107 phosphorylation by c-Abl affects Gal-3
cleavage by PSA and influences the localization and role of
this lectin in PCa [49].
An evaluation of Gal-3 expression in tissue microarrays
prepared from 83 tumor, 78 adjacent-benign, and 75 benign
tissues obtained from 83 patients who had undergone prosta-
tectomy for clinically localized PCa suggests that the expres-
sion of this lectin could be used as predictor of biochemical
recurrence [55]. In this study,multivariate analysis (including
age, Gleason score, T stage, seminal vesicle invasion, or pre-
operative PSA and Gal-3 staining) demonstrated nuclear and
cytoplasmic localization of Gal-3 in benign, adjacent-benign
and tumor tissues with a significant decrease of its expression
from benign to adjacent-benign, and to tumor tissues.These
results convincingly demonstrate thatGal-3 staining intensity
correlates with biochemical recurrence.
As Gal-1 and Gal-3 are the two best studied Gal members
in cancer and particularly in PCa, we wondered if other
Gals could show a particular profile of expression. As Gals
play fundamental, although divergent, roles in diverse tumor
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BHP T1 T2 T3 T4
Gal-1 Gal-3
Gal-8
Gal-9
Gal-4 Gal-12
Figure 4: Profile of expression of galectins throughPCa evolution. Radical prostatectomieswere classified according toTNMscale. Specimens
(푛 = 61) covered all stages of prostate cancer evolution, including T1 (tumor detected in less or 5% of the tissue), T2 (tumor confined to
the prostate), T3 (tumor that extends beyond the prostatic capsule), and T4 (tumor that invades structures other than seminal vesicles), in
addition to BHP. Immunohistochemistry was conducted on paraffin-embedded tissue samples as previously described [23].The figure shows
proportional expression of each Gal at different stages of PCa.
microenvironments [57], identification of the “galectin-
specific signature” of PCa is critical for diagnostic, prognostic,
and therapeutic purposes. For this, we decided to study the
expression of almost all Gals in human prostate cancer cells.
Firstly, in order to delineate the Gal expression profile of PCa
progression, we examined the Gal transcriptional pattern of
several human PCa cell lines, which are representative of
different stages of the disease. These include LNCaP and
castration-resistant cell lines 22Rv1 or PC-3, which either
express or do not express the androgen receptor (AR),
respectively, and display a more aggressive behavior in vivo
[58–60]. Total RNA was extracted in the log phase of growth
in culture and analyzed by quantitative RT-PCR. Remarkably,
Gal-1 was found to be the most abundantly expressed Gal
in all cells analyzed and its expression was higher in those
PCa cells exhibiting a more aggressive behavior in vivo.Gal-8
mRNA, which has been postulated as a PCa marker [42, 61],
was found to be ubiquitously expressed, although being at
modest levels in all cell lines tested. Gal-3 mRNA was only
detected in androgen-independent, AR negative PC-3 cells.
Transcripts for all other Gal family members (Gal-2, -4,
-7, -9, -10, and 13), however, were found to be expressed at
very low levels. To further delineate “the galectin-specific PCa
signature,” we profiled expression of Gals at the protein level
(mainly focusing on those members of the family showing
higher transcriptional levels). Immunocytochemical analysis
of PCa cells confirmed that Gal-1 is the most abundantly
expressedGal in all PCa cells analyzed showing a pronounced
upregulation in stages of more aggressive behavior. On the
other hand, Gal-3 was predominantly expressed in the PC-
3 cell line, and Gals-8 and -9 showed the modest expression
in all cell lines analyzed. In agreement with transcriptional
profiles, other Gal family members showed lower levels of
protein expression. Altogether, these results indicate a fine
regulation of Gal expression, mostly at the transcriptional
level, in PCa cells characterized by distinct phenotypes,
hormone-dependence, and aggressive behavior [23].
The differential expression of Gals in PCa cell lines
prompted us to investigate the profile of these lectins in
biopsies obtained from 60 patients naive of any therapeutic
treatment. Samples were classified according to TNM classi-
fication (UICC, 2002). A large spectrum of PCa phases, T1,
T2, T3, and T4 in addition to a benign stage (BHP), were
represented. Gal expression was analyzed by IHC in paraffin
embedded tissue samples. These results are summarized in
Figure 4 and show the evolution of the expression of Gals,
essentially Gals-1, -3, -4, -8, -9, and -12 during the progression
of PCa. Similar to tumor cell lines, Gal-1 exhibited the highest
expression levels which increased progressively during tumor
evolution towards more aggressive stages. Further analysis
revealed that, in addition to its expression in tumor cells,
Gal-1 is also expressed, although at a lower levels, in tumor-
associated stroma and normal adjacent tissue.These findings
broaden the results reported previously by Ellerhorst et al.
[52] and Clausse et al. [24], who showed selective Gal-1
expression in endothelial cells (EC) in PCa. On the other
hand, although typically expressed at lower levels, Gals-3,
-4, -9, and -12 gradually decrease as the disease advances.
Conversely, Gal-8was highly expressed, but no apparent reg-
ulation could be observed during disease progression.Thus, a
“galectin-specific signature” characterized by up-, down-, or
nonregulated family members delineates PCa progression in
patients biopsies, suggesting novel biomarkers of disease evo-
lution. Particularly, we show for the first time Gal-1 expres-
sion as a hallmark of PCa aggressiveness, suggesting a major
target for anticancer therapies [23].These changes onGal pro-
files may have important impacts on tumor biology as they
are reported to affect several cellular processes, developed in
the following chapters.
4. Effects of Galectins on Apoptosis
Galectins have contrasting effects on apoptosis. While Gal-
1 is an apoptosis promoter, Gal-3 shows both pro- or anti-
apoptotic effects depending on its subcellular localization in
PCa. For instance, induction of differentiation and apoptosis
by butyrate was investigated in four human PCa cell lines
including LNCaP [21]. Treatment of PCa cells with butyrate
resulted in increased Gal-1 expression in a time- and dose-
dependent manner followed by induction of apoptosis. As
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LNCaP cells do not express (or express low levels of) Gal-
1, transfection with a Gal-1 expression vector inhibits LNCaP
cell growth and increases the apoptosis rate. Therefore, Gal-
1 may function downstream in the pathway of butyrate-
induced differentiation and apoptosis [21].
It is well demonstrated that Gal-1 could act extracellularly
to induce apoptosis in glycopermissive cells [62]. In PCa,
Gal-1-induced apoptosis is highly dependent on the O-
glycosylation of cells. Expression of alpha-2,3-sialyltrans-
ferase-1 blocks O-glycans elongation and protects LNCaP
subclone from Gal-1-induced apoptosis [22]. This original
work shows that the expression of Gal per se is not the final
determinant of cell apoptosis; instead, regulation of lectin
expression and the glycan repertoire determines the final
phenotype, sensitivity, or resistance to apoptosis induction.
In an opposite way, Gal-3 has a dual role in controlling cell
apoptosis depending on the PCa cellmodel. To studywhether
Gal-3 regulates drug-induced apoptosis, Raz’s group either
transfected LNCaP cells with Gal-3 or silenced Gal-3 expres-
sion in PC-3 cells. They tested sensitivity to cis-diammine-
dichloroplatinum and showed apoptosis induction in Gal-
3 expressing LNCaP, more precisely through inhibition of
cytochrome c release and caspase-3 activation [28]. On
the contrary, Gal-3 knockdown in PC-3 cells leads to cell-
cycle arrest at G(1) phase, upregulation of nuclear p21, and
hypophosphorylation of the retinoblastoma tumor suppres-
sor protein (pRb), with no effect on cyclinD1, cyclin E, cyclin-
dependent kinases (CDK2 and CDK4), and p27 protein
expression levels [29].
More interestingly, Gal-3 also shows a dual role upon its
subcellular localization promoting or alternatively inhibiting
apoptosis in Gal-3 transfected LNCaP cells. While nuclear
Gal-3 targeting allowed by fusion with nuclear localization
sequences was found to have proapoptotic properties, the
cytoplasmic form is antiapoptotic and promotes tumor pro-
gression [30]. These results clearly demonstrate a fine par-
ticipation of Gals in the control of survival and proliferation
processes in tumor cells.
5. Galectins in Cancer Cell
Adhesion and Metastasis
During tumor progression, malignant cells acquire the abil-
ity to overcome cell-cell adhesion and invade surrounding
tissues, a state known as metastatic disease. It is important
to understand this process and identify inducers of tumor
metastasis in order to develop treatments that target meta-
static cells for long-term tumor regression.
Galectin-1 is involved in numerous biological func-
tions including capillaries formation. Gal-1 is expressed by
endothelial cells (EC) from capillaries infiltrating the tumor
tissue in 64% of the cases of 100 human prostate carcinoma
samples, but in only few cases (7%) in endothelial cells in the
adjacent nontumoral stroma. These results strongly suggest
that tumor cells induce Gal-1-expressing EC allowing tumor
adhesion to vessel endothelium. To verify this hypothesis,
Clausse and colleagues incubated HUVECs cells with condi-
tioned media from PC-3 or DU145 prostate carcinoma cells
and they observed a significant increase of Gal-1 protein
expression. Additionally, both PC-3 conditioned medium
and recombinant Gal-1 induced increased PC-3 cells adhe-
sion to EC, while conditioned media complemented by an
anti-Gal-1 antiserum abolished this modulation [24]. It is
important to note that no cell adhesion to EC was observed
when normal lymphocytes were used instead of PC-3 cells
under the same conditions. This places Gal-1 as a molecular
link of the specific EC/tumor interaction and suggests an
additional tumor-based immune escape mechanism. In the
same way, expression of Gal-1 in the cell surface of LNCaP
also showed the lectin ability to modulate adhesion to the
ECM [25] revealing a general function of Gal-1 in PCa cell-
matrix interactions.
Capillary formation is essential for tumors to obtain
nutriments as well as for migration and the metastasis pro-
cess. Interactions of metastatic cancer cells with blood vessels
are critical during early stages of cancer metastasis but also
in the lodge of tumor cells in specific organs and tissues. In
2005, Glinskii and colleagues demonstrated that mechanical
entrapment alone, in the absence of tumor cell adhesion to
blood vessel walls, is not sufficient for metastatic cell arrest in
the microvasculature of the target organ. The analysis of the
frequency and location of fluorescent tumor cells in different
organs and tissues following intravenous inoculation revealed
that PCa cells go into a wide variety of tissues and organs
but not to the lung capillary bed. Results showed that arrest
of metastatic cells in target organ microvessels is not a
consequence of mechanical trapping, but is supported pre-
dominantly by intercellular adhesive interactions mediated
by cancer-associated Thomsen-Friedenreich (TF) antigen
and Gal-3 [35]. Additionally, carbohydrate moieties of the TF
antigen (Gal훽1,3GalNAc) on the surface of endothelial cells
could be efficiently recognized by Gal-3, thus priming them
for harboring metastatic cancer cells [34].
In mCRPC, bones are a privilege site for the metastatic
disease that causes osteoblastic growth. However, the mecha-
nisms that contribute to bone metastasis are poorly under-
stood. It was suggested that the bone provides a favorable
environment for PCa cells growth and that tumor cells pref-
erentially bind to bone marrow EC. To verify this hypothesis,
cancer cell adhesion to a human bone marrow endothelial
(HBME-1) cell and EC lines from other organs was assessed.
In vitro, PCa cells adhered preferentially to HBME-1 when
compared with endothelium derived from other sources, and
this adhesion was inhibited by anti-Gal-3 and anti-LFA-1 sera
[36]. These data showed that bone metastasis of PCa cells
is essentially caused by their preferential binding to bone
marrow endothelial cell and in part mediated by cell-cell
adhesion via Gal-3 [36]. As in non-small-cell lung cancer,
collagen XXIII is a transmembrane protein previously shown
to be upregulated, at least in part, through Gal-3, and whose
expression facilitates metastases formation in PCa model
[37]. This suggests a potential role for collagen XXIII in
combination with Gal-3 in mediating metastasis by facilitat-
ing cell-cell and cell-matrix adhesion as well as anchorage-
independent cell growth.
Being currently incurable, PCa metastasis has a remark-
able ability to spread to the skeleton. Advanced PCa cells
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are essentially characterized by bonemetastasis that predom-
inantly causes an osteolytic phenotype. In a PC-3 cellular
model, it has been shown that both the conditioned media
from these PCa cells containing Gal-1 and recombinant Gal-1
inhibited the osteoblastic proliferation and differentiation of
human bonemarrow stromal (hBMS) cells.Thus, the authors
hypothesized that Gal-1 could be involved in the osteoblastic
response caused by PCa cells metastasizing to the bone, by
affecting the matrix mineralization [26]. To date, studies in
animalmodels still fail to demonstrate the role ofGal-1 in PCa
metastasis process.
Gal-3 is the only member of this family of lectins that
was studied in vivo: Gal-3 expression drives spontaneous
metastasis using rat PCa models such as Dunning or Copen-
hagen rat [38]. The oral administration of modified citrus
pectin (MCP, pH-modified), a soluble component of plant
fiber derived from citrus fruit, revealed inhibition of cell-cell
interactions mediated by cell surface carbohydrate-binding
Gal-3 molecules. In fact, the presence of Gal-3 in Dunning
PCa cell lines (MAT-LyLu cells) and primary human prostate
carcinoma was demonstrated by immunoblotting and IHC.
Lung metastatic colonies were observed after subcutaneous
injections ofMAT-LyLu cells in posterior legs ofmale Copen-
hagen rats, while continuous administration of MCP in
drinking water reduced the number of lung metastases. MCP
had no effect on the growth of the primary tumors suggesting
that the reduction of lung metastases was caused by both
interference with migration or tumor adhesion such as cell
adhesion to EC, and the spreading of tumor cells. As MCP
is not an exclusive inhibitor of Gal-3, further studies are still
required to specifically target this galectin and determine its
role in normal and cancerous prostate tissues and the ability
of Gal-3 targeting to inhibit prostate metastasis in animal
models. As we previously described, interactions mediated
by the cancer-associated TF glycoantigen and Gal-3 play an
important role in several rate-limiting steps of cancer metas-
tasis such as cell adhesion to bone marrow endothelium,
homotypic tumor cell aggregation, and clonogenic survival
and growth [34, 35], and it was only recently shown that Gal-
3 influences bone metastasis in a mouse model after intracar-
diac injection of luciferase-expressing PC-3 cells in nudemice
[39]. Indirect targeting of Gal-3 by using daily intraperitoneal
administration of Lac-l-Leu, which binds and inhibits Gals by
mimicking essential structural features of the TF-Ag, affects
PCa cell adhesion to bone marrow endothelium, homotypic
aggregation, transendothelial migration, clonogenic growth,
and final spreading of tumor cells to the skeleton [39].These
results were recently confirmed by others demonstrating
inhibition of tumor-endothelial cell interactions and lung
metastasis using TFD100 (a purified glycopeptide acting as
competitor in Gal-3 binding to TF-Ag on the surface of most
cancer cells [33]), or using MCP in combination with other
drugs such as ProstaCaid [41]. Altogether, they highlight the
impact of Gal-3 on invasive behavior in human PCa cells in
vitro. As Gal-3 is not expressed in advanced stages of the
disease, other factors act to promote spreading of tumor cells
and have to be identified to attempt to cure mCRPC patients.
Galectin-8 was initially called Prostate Cancer Tumor
Antigen-1 (PCTA-1) because of its exclusive expression in
neoplastic prostate cells and its absence in normal prostate
tissue. In fact, Gal-8 levels of expression positively corre-
late with certain human neoplasms [42]. Gal-8, like other
galectins, is a regulator of cell adhesion depending on its for-
mulation.Thus, immobilized protein acts as a potent matrix
protein in promoting cell adhesion by ligation and clustering
of a selective subset of cell surface integrin receptors and
triggering signaling cascades including Tyr phosphorylation
of focal adhesion kinase and paxillin [63]. In contrast, when
present in excess as a soluble ligand, Gal-8 forms complexes
with integrin that negatively regulates cell adhesion and
tumor properties such as growth and metastasis [43]. No
current evidence exists about these potential roles of Gal-8
in animal models to understand why Gal-8 is only expressed
in prostate tissue at neoplastic stages.
Interestingly, glycosyltransferase-mediated regulation of
carbohydrate expression on cell membrane-glycoconjugates
has been recently shown to be involved in migration and
invasion properties of the PC-3 cell line. It is well known that
Gals link to tri- and tetrabranched N-glycans forming multi-
valent lattices that enhance cell surface residency of growth
factor receptors and focal adhesion turnover. Silencing N-
acetylglucosaminyltransferase I (MGAT1, the first enzyme
of N-glycans biogenesis) by RNA interference in PC-3 was
enough to inhibit cell invasion by affection of focal adhe-
sion and microfilament organization, thus generating a less
motile phenotype. More importantly, orthotopic injection of
MGAT1-silenced PC-3 in nude mice revealed a decrease in
primary tumor growth and poor incidence of lungmetastases
as well [64]. Not only N-glycans should be considered as
potential regulators of Gal functions in PCa but also O-
glycosylation confers LNCaP cells susceptibility to Gal-1-
induced apoptosis [22].
6. Galectins as Inducers of
Tumor Angiogenesis
Cancer metastasis involves a series of steps including angio-
genesis, detachment of tumor cells from the primary tumor,
intravasation, evasion of host defense, arrest and attach-
ment at a distant site, extravasation, dormant survival, and
establishment of new growth. During extravasation, tumor
cells bind to endothelial cells through protein, carbohydrate
interactions and penetrate through the endothelium and
basement membrane. Besides providing tumors with nutri-
ents, newly formed capillaries constitute a potential escape
route for tumor cells, thus favoring metastatic dissemination,
and also provide an access to host immune cells.
Analysis of Gal-1 expression in EC from 100 PCa patients
who had undergone a radical prostatectomy for localized
prostate cancer (Gleason score from 2 to 10) revealed
increased frequency of Gal-1 expression in capillaries infil-
trating the tumor compared to those present in the non
tumoral adjacent tissue [24]. Although EC do express Gal-
1, in vitro culture of HUVEC cells in normal medium
complemented by conditional media from PC-3 or DU145
led to enhanced Gal-1 expression in EC [24]. These results
demonstrate that secreted factors from tumor cells influence
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Gal-1 expression in capillaries cells and promote specific
attachment of tumor cells to EC. This heterotypic cell inter-
action is essentially due to Gal-1 produced by tumor cells as
Gal-1 blocking antibodies inhibited this effect [24]. However,
further experiments are required to unveil the role of this
interaction in the evolution of the disease.
Because Gal-1 expression is associated with PCa aggres-
siveness and has emerged as a novel proangiogenic factor in
other tumor types [65, 66], we decided to further examine
whether expression of this lectin correlates with the fre-
quency of blood vessels in low grade or high grade human
PCa [23]. For this purpose, we evaluated coexpression of
Gal-1 and CD34 by IHC analysis of a human PCa tissue
array comprised of 29 paired cores of invasive PCa. A
positive correlation between Gal-1 and CD34 was selectively
detected in arrays of human PCa, but not in arrays of human
breast cancer which served as control, suggesting a tissue-
specific proangiogenic effect of this lectin in cancer. This
selectivity is consistent with the ability of Gal-1 to induce
angiogenesis of oligodendroglioma [65], B16melanoma [67],
and Kaposi’s sarcoma [68], but not Lewis lung carcinoma
[69]. This correlation between Gal-1 expression and the
number of blood vessels was also verified when the tumor
compartment was compared to nonmalignant areas and was
even more pronounced in high grade compared to low
grade tumors [23]. Complementary to what was previously
reported by Clausse and colleagues [24], we demonstrated
that tumor cells are the major source of Gal-1. While some
inconsistencies are observed between studies addressing the
relative expression of Gal-1 by stroma versus tumor cells
probably by differences in methodological approaches, its
functional impact on other cancers such as melanoma or
lung carcinoma was elegantly assessed in mice by comparing
the functionality of these cellular compartments under Gal-
1 deficiency or wildtype conditions. Those results clearly
demonstrated tumor as the main Gal-1 source in controlling
tumor growth [69]. Another possibility that must be taken
into consideration is the hypothesis that EC are able to capt
tumor derived-Gal-1 through mechanisms that must be fully
understood [67].
Given the promising therapeutic value of anti-angiogenic
strategies in advanced androgen-refractory PCa [70], wewere
prompted to examine the role of Gal-1 in PCa angiogenesis.
We first evaluated the effect of conditionedmedium obtained
from 22Rv1 (PCa CM), a Gal-1-positive PCa cell line, on
in vitro tubulogenesis. PCa CM induced the formation of
tubular-like structureswhen added to EC.The involvement of
Gal-1 in this process was assessed by using an anti-Gal-1 neu-
tralizing mAb, which considerably reduced the formation of
these structures [23].These in vitro effects of Gal-1-expressing
PCa cells on endothelial cell morphogenesis prompted us to
investigate the role of this lectin in angiogenesis in vivo. Our
experimental approach consisted in the s.c. injection of 22Rv1
PCa cells in Matrigel plugs. Importantly, we were able to dif-
ferentiate the source of Gal-1 (tumor and microenvironment
versus tumor alone): firstly, a blocking anti-Gal-1 mAb was
added to the mix (total Gal-1 inhibition independently of its
source is to be expected); alternatively, we used 22Rv1 tumor
cells transduced with a human specific Gal-1 shRNA-coding
lentivirus (thus inhibiting tumoral Gal-1 expression alone). A
marked reduction of microvessel density was observed using
both experimental approaches, indicating that tumor cells
are the main source of Gal-1, at least at early time points
of tumor implantation and neovascularization. Confirming
this reasoning, intermediate effects were observed when Gal-
1 was partially downregulated in PCa cells. Altogether, these
in vitro and in vivo results reveal a key role of Gal-1 in PCa-
induced angiogenesis. More importantly, we showed that in
vivo silencing of Gal-1 expression by tumor cells does not
interfere with other pro- or anti-angiogenic factors such as
VEGF or thrombospondin and bFGF, revealing the prepon-
derant role of Gal-1 in promoting PCa neovascularization and
suggesting Gal-1 as a new potent target for clinic therapeutic
approaches in advanced PCa patients [23].
Gal-3 could also act as an angiogenic inducer by recog-
nizing the TF disaccharide antigen present on the surface
of most cancer cells. Using a purified glycopeptide TFD100
that binds Gal-3 with picomolar affinity, the authors blocked
Gal-3-mediated interactions and inhibited angiogenesis of
PC-3 tumors in mice [33]. In this PC-3 model, Gal-4 and
Gal-9 also efficiently bind to TFD100 and thus are impli-
cated in PCa. Consequently, silencing of these molecules
causes strong reduction of in vitro tubulogenesis and VEGF-
induced blood vessels formation in Matrigel plug assays
[33]. Altogether, these results highlight a major role of the
interactions between Gals and their corresponding glyco-
ligands in determining tumor-associated angiogenesis.
7. Galectins as Immune Tolerance Inducers in
Prostate Cancer
An efficient immune response against pathogens or tumors
needs effective egress of lymphocytes from the blood into
the target tissue. This process is allowed in part by spe-
cific EC proteins promoting lymphocyte adhesion to and
migration across endothelium. Other molecules negatively
regulate transendothelial migration of lymphocytes. Gal-1
is one of the best studied members that acts as inducer
of immune tolerance in cancer [10]. As it was previously
showed, Gal-1 expression could be induced in ECby neighbor
tumor cells [24], but it is well known that this lectin could
regulate the inflammatory setting,modulating T cell cytokine
production and triggering T-cell death [17, 27]. Migration
of T-cell lines through Matrigel is inhibited by EC treated
with either PCa conditioned media containing Gal-1 or with
Matrigel coated with recombinant Gal-1. This inhibition is
reverted by using an anti-Gal-1 serum, demonstrating that
transendothelial migration of T cells is negatively regulated
by Gal-1-producing EC. More importantly, the inhibition is
due to decreased adhesion of T-cells to Gal-1 expressing
EC rather than T cell death. In fact, T-cell treatment with
benzyl-a-GalNAc, which reduces core 2O-glycan expression
thus blocking Gal-1 recognition, inhibits Gal-1-induced T
cell death. Polarization of CD43 molecule on T cells is
essential for T cell migration. Interestingly, Gal-1-coated
ECM enhanced clustering of CD43, which contributes to the
inhibitory effect on T-cell migration [27].The role of Gals as
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active controllers of immunological tolerance in PCa is a field
that is still open to new discoveries.
8. Galectins as Molecules with Prognosis and
Therapeutic Value in Prostate Cancer: From
Animal Models to Clinical Settings
PCa is curable only when detected in its early stages as
a result of both prostate-specific antigen (PSA) blood test
screening and digital rectal exam. When patients suffer from
metastatic disease and undergo mCRPC, docetaxel-based
combination chemotherapy is the only available therapy that
has demonstrated a survival benefit in 50% of these advanced
stages of PCa. Moreover, FDA approved new therapies,
most are being evaluated on clinical trials and are based
on targeting the angiogenesis, the tumor microenvironment,
or immunotherapy [71]. All these drugs showed improved
overall survival (OS) of the mCRPC patients for 3–5months.
One of these drugs is PROVENGE (sipuleucel-T), a dendritic
cell-based immunotherapy targeting the prostatic acid phos-
phate (PAP), an antigen expressed in more than 95% of PCa
[72].The treatment consists in ex-vivo loading of autologous
dendritic cells with the recombinant antigen which is PAP-
GM-CSF: chimera of PAP and the granulocyte-macrophage
colony-stimulating factor (GM-CSF), an immune adjuvant.
This new treatment is only intended for men with asymp-
tomatic or minimally symptomatic and metastasized PCa
that are resistant to standard hormone treatment. In con-
trolled and multicenter clinical trials, several adverse events
have been reported in the PROVENGE group, which include
acute infusion reactions (occurring within 1 day of infusion)
and cerebrovascular events. The most common adverse
events (incidence ≥ 15%) reported were chills, fatigue, fever,
back pain, nausea, joint ache, and headache [73].
Xtandi (enzalutamide), an androgen receptor antagonist,
is a new PCa treatment approved by FDA in August 2012
to treat mCRPC patients, with spreading or recurred cancer
even with medical or surgical therapy and resistant to
docetaxel-based chemotherapy.
Finally, Xofigo was approved by FDA in mid-2013 for
patients with CRPC, symptomatic metastases that spread
to bones but not to other organs as in visceral metastatic
disease. Xofigo binds with minerals in the bone to deliver
radiation directly to bone tumors, limiting the damage to
the surrounding normal tissues. Xofigo is an alpha particle-
emitting radioactive therapeutic agent (radium-223 dichlo-
ride). The most common side effects were nausea, diarrhea,
vomiting, swelling of the leg, ankle, or foot, and blood cells
abnormalities with less than 5months of improved OS.
Therefore, it is critical to identify new molecular targets
to efficiently cure advanced cancers. A limited number of
studies consider potential implications of individual Gals in
the modulation of the metastatic process, yet the role of these
essential proteins in vivo is still unclear. Under this scenario,
a more deeply comprehension of the influence of Gals in
evolution of PCa could help to define new drugs that treat
advanced and mCRPC patients. For instance, the ratio of
phosphorylated/dephosphorylated Gal-3 might be used as a
complementary value to that of PSA for prognosis of PCa
[49].
From a therapeutic point of view, Gal-3 has been con-
jugated to the chemotherapy drug 5-Fluoracil and delivered
to PC-3 tumors by using a copolymer system named Gal-
3-targeted HPMA copolymer-(G3-C12-)5-Fluorouracil con-
jugates. This drug showed in vitro inhibition of PC-3 cell
migration after wounding and displayed a potent antitumor
activity against PC-3 tumor xenografts in nudemice [40].
Drug resistance is a major obstacle for PCa therapy, but
its underlyingmechanisms are not clear, especially in patients
with advanced stages of the disease. A comparative proteomic
profiling of camptothecin- (CPT-) resistant PC-3 and CPT-
sensitive LNCaP human PCa cell lines identified a signature
of 144 proteins with different expression levels between the
two cell lines that are suggested to contribute to the develop-
ment of drug resistance [74]. In this respect, Gal-3 is highly
expressed in PC-3 cells, whereas it is not detectable in LNCaP.
The expression level of these proteins and/or mRNAs could
be a useful parameter to evaluate chemotherapy resistance
in clinical specimens of PCa [74]. The same conclusion was
drawn when Gal-3 silencing induced increased cisplatin-
induced apoptosis of PC-3 cells [31]. Resistance to apoptosis
is a critical feature of neoplastic cells; Gal-3 either inhibits
anticancer drug-induced apoptosis or promotes cell death
depending on its subcellular localization.These findings sug-
gest that Gal-3 targeting could improve the efficacy of anti-
cancer drug chemotherapy in PCa [28]. In fact, Gal-3 presents
a domain like NWGR anti-death motif of Bcl-2 family which
confers antiapoptotic properties through regulation of Bad
protein and suppression of themitochondrial apoptosis path-
way [75].Thus, Gal-3 showsmultifunctional oncogenic func-
tions such as the regulation of tumor proliferation, angiogen-
esis and apoptosis. In this sense, sensibility to proapoptotic
agents like cis-platin and etoposide is higher in Gal-3 neg-
ative PCa cell lines than in Gal-3 expressing cells [28, 32].
These observations imply that Gal-3 inhibits anticancer drug-
induced apoptosis and, consequently, Gal-3 targeting could
improve the efficacy of anticancer drug chemotherapy in PCa.
However, as Gal-3 is only expressed in early but not in late
stages, it is unlikely that this kind of treatment could serve as
new curative options for mCRPC patients.
Recently, we confirmed pioneer studies of Gal-1 as a
tumoral marker of poor prognosis for PCa patients [53], and
we showed a regulated expression of several Gals with diag-
nostic value. In fact, strong increase ofGal-1, decrease ofGals-
4, -9, and -12, and gradual decrease to complete extinction of
Gal-3 expressions could define the stage of PCa progression
using IHC as a simple method to analyse Gal expression
in available patients samples (Figure 4 and [23]). As shown
in Figure 4, comparison of Gal expression could define PCa
patient stage: T1, T2-T3, and T4; however, while T1 and T4
could be easily identified, it appears difficult to differentiate
T2 to T3 stages since Gal profile is similar between these two
intermediate stages.
Galectins are not only shown to be involved in anti-
apoptotic functions and edition of immune tolerance; several
studies clearly revealed their proangiogenic functions in can-
cers [68, 76–78]. Interactions of metastatic cancer cells with
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vascular endothelium are critical during early stages of cancer
metastasis. Various investigations, not developed in this
review due to space limitations, showed Gals as angiogenic-
regulatory proteins. For instance, Gal-3 was suggested as a
new target to treat breast cancer patients [34], and Gal-8 as
a new modulator of EC migration and angiogenesis [79].
In the case of PCa, we recently demonstrated that Gal-1 is
the principal inducer of neoangiogenesis [23] and could be
used as a novel target for anti-angiogenic therapies in human
advanced PCa.
9. Conclusion
While localized PCa can be cured, metastatic and advanced
prostate cancers pose a significant therapeutic challenge.
We and others identified a “galectin-regulated signature”
as new prognostic markers and molecular targets of novel
therapeutic avenues for preventing metastasis. Tumor metas-
tasis is a multistep process involving several cellular and
molecular interactions. Recognition of glycoconjugates by
galectins regulates tumor behavior through both intrinsic
as well as extrinsic signals involving modulation of homo-
typic cell aggregation, tumor cell apoptosis, angiogenesis,
and tumor immune escape [9]. In fact, Gal-1 expression
regulates prostate tumor cell resistance to apoptosis before
becoming castration resistant [22]. As shown in breast cancer,
Gal-3 containing NWGR amino acid domain sequence as
bcl-2 gene family also could act as antiapoptotic protein
independently of Bcl-2, Bcl-XL, or Bax proteins [80]. Thus,
both Gals may contribute to tumor survival and to the
selection process that is characteristic of the evolution of
this type of cancer. However, not only the tumor itself but
also the surrounding tissues and the complex network of
stromal, endothelial, and immune cells that interact within
the tumor microenvironment should be considered. In this
respect, cancer cells not only control the expression of their
own Gals but also modulate Gal expression in environmental
tissues [24]. Gals regulate cell-cell and cell-ECM interac-
tions. Surprisingly, different members of the family elicit
particular and sometimes antagonic effects. In fact, anti-Gal-
3 monoclonal antibodies (mAbs) prevent the adhesion of
prostate tumor cells to bone marrow endothelial cells [36].
In addition, Gal-1 increases, while Gal-8 reduces tumor cell-
ECM interactions [52, 63, 81]. Altogether, these effects may
contribute to shaping a favorable tumor microenvironment
that allows distant dissemination of transformed cells.
Despite these observations, there are relatively few in
vivo studies addressing the source and function of Gals
and exploring these phenotypes in PCa [35, 38, 82, 83]. In
fact, expression levels of Gals-1 and -3 were reported to
be associated with the growth and metastatic properties of
prostate tumors and may correlate with a poor prognosis
[24, 35, 38, 52, 82, 84]. During the last two decades, Gal-
3 was the only member of the family whose role has been
addressed using in vivo experimental models. A key role of
this glycan-binding protein in the formation of spontaneous
metastasis was demonstrated using peptide inhibitors in
experimental animal models of PCa [38, 39]. Moreover,
tumor cell expression of Gal-3 has been shown to delineate
the transition from benign prostate glands to hormone-
resistant malignant disease [84], and its regulated expression
is associated with promoter methylation [85]. Silencing Gal-
3 results in decreased migration, invasion, and proliferation
of PCa cells [29]. Taking into consideration these results,
Gal-3 emerges as a key lectin that plays an essential role in
the formation of metastases but not in the progression of
advanced disease. Moreover, Gals-1 and -3 were both found
in the nucleus of cells [86, 87].The importance of bothGals in
presplicing RNA activity has been demonstrated by depleting
these lectins fromnuclear extracts, which causes inhibition of
the splicing activity [88, 89].These properties and the relation
with other nuclear factors such as splicing or transcriptional
factors should be explored inPCa to identify new intracellular
partners that could represent new therapeutic targets and
signaling pathways as well.
Galectin profile in cancermay be intrinsically determined
and consequently considered as biomarkers of cell transfor-
mation. In this respect, we can assume that each type of
tumor can be associated with characteristic profiles of Gals.
Our study on PCa cell lines and patient samples proposes a
particular profile ofGals throughdisease progression [23, 76].
However, tumor cell must be considered in association with
its microenvironment. In this respect, most of the cancers
are characterized by particular inflammatory processeswhere
bidirectional dialogues between tumor, resident, and infiltrat-
ing cells result in changes on cell surface expression of glycans
and lectins. It is possible that Gals may be an acute phase
reactants produced in response to tumor-associated stress.
Under this view, changes in Gal profiles could represent
an epiphenomenon due to associations with inflammation.
Whatever the real cause/effect, changes inGal expressionmay
be exploited as accurate tools for diagnosis, prognosis, and
probably therapeutic purposes in cancer.
In spite of considerable progress in dissecting the func-
tions of individual Gals, an integrated portrait of the “galectin
signature” of the human PCa microenvironment is still miss-
ing. In addition, it is not clear which cellular compartment
expresses a givenGal andwhen this expression is required for
cancer progression.While onlyGals-1 and -3were extensively
studied in PCa, these Gals have been already shown to be
potential new factors that participate directly in PCa progres-
sion and cancer drug resistance. In fact, Raz’s group showed
that phosphorylated Gal-3 is responsible for drug resistance
in PCa and should be considered as new target to improve
efficiency of chemotherapeutic agents such as cisplatin and
etoposide [32]. We demonstrated that Gal-1 expressed by
the tumor is essential and sufficient to promote neovascu-
larization independently of classical angiogenic pathways.
This strongly supports the idea of Gal-1 targeting as a new
anti-angiogenic therapy for advanced PCa. Additionally, we
showed that Gals-4 and -12 suffered decreased expression
through PCa evolution, but the role of these Gals in PCa is
a field that lacks a more deeply understanding.
Finally, Gal-8 is another tandem-repeat Gal of impor-
tance in PCa. This Gal has been defined first in 1996 [42]
and 2000 [61] as PCa biomarkers and six years after as a
potential responsible for hereditary PCa [90]. To date, no
study has been performed to understand why this particular
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Gal is generally expressed in all tissues but it only turned on
in neoplasic prostatic tissues and is absent in normal prostate.
Despite these important characteristics, studies about the role
of Gal-8 in PCa are still missing.Thus, its use as a therapeutic
target in this disease should be further explored.
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